Pregabalin
Product Images NDC 68071-2330

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68071-2330). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2330 9)

Label for Pregabalin 50mg capsules by NuCare Pharmaceuticals, Inc., showing a quantity of 90 capsules. The label includes NDC 68071-2330-9, storage instructions at 59-86°F, and warnings to keep out of reach of children. It also notes the prescription-only status and manufacturer details for SciGen Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at doses of 200 mg, 100 mg, and 25 mg three times a day with placebo, showing trends of patient improvement across increasing pain relief percentages.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent of patients improved versus percent improvement in pain from baseline. It shows two lines, one for Pregabalin 100 mg three times a day and one for placebo, illustrating patient response differences based on pain improvement percentage.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, 150 mg twice daily, 75 mg twice daily, and placebo, with higher doses generally showing greater patient improvement.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 100 mg and 200 mg three times a day compared to placebo. The graph displays three lines representing each group, illustrating differences in pain improvement over various percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The graph shows three differently styled lines representing these groups, with the x-axis labeled percent improvement in pain and the y-axis labeled percent of patients improved.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph showing responder rates (%) from two clinical studies, Study E1 and Study E3. Study E1 compares placebo and various daily dosages of Pregabalin (50 mg, 150 mg, 300 mg, 600 mg), all administered twice daily (BID). Study E3 compares placebo, 300 mg/day BID, and 600 mg/day once daily (TID). Statistically significant differences from placebo are marked with an asterisk.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction (median percent change from baseline) on the y-axis versus dose in mg/day on the x-axis for Pregabalin. It shows data from four studies identified by different symbols. The graph highlights significant p-values associated with seizure reduction at various doses.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 800 mg, 450 mg, 300 mg daily doses, and placebo. The chart compares pain improvement outcomes across different dosing groups and placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR (loss to retreatment) over a period of 180 days for Pregabalin versus placebo. The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis represents days from 0 to 180. The Pregabalin group is depicted with a solid line showing a higher percentage of subjects without LTR over time compared to the placebo group, which is shown with a dashed line.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph depicting the percent of subjects improved over various percentages of improvement from baseline to Week 12 BOCF. The x-axis represents the percent improved from baseline to Week 12 BOCF, ranging from 0% to 100%, while the y-axis shows the percent of subjects improved, also from 0% to 100%. Two lines are compared: Pregabalin (solid line) and Placebo (dashed line), with Pregabalin showing consistently higher percentages of improved subjects than Placebo across the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing percent of subjects improved between Pregabalin and Placebo over different percent improvement thresholds from baseline to week 16 using BOCF analysis. The x-axis shows increasing percent improvement (0 to 100), and the y-axis shows percent of subjects improved (0 to 100). Pregabalin is represented by a solid line, Placebo by a dotted line, indicating higher improvement rates for Pregabalin at most thresholds.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula for calculating creatinine clearance (CLcr), factoring in age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment multiplier of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of the active ingredient Pregabalin, depicted as a molecular diagram showing its amino acid derivative framework with a carboxyl group (CO2H) and amine group (NH2). No additional labels or text are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.